AbbVie and Mingenix Biopharmaceutical (Beijing) Co., Ltd. announced the signing of a licensing agreement to jointly develop FG-M701. FG-M701 is a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) that is in preclinical development. Compared to the first generation of TL1A antibodies, FG-M701 has the potential to be the best of its kind in terms of functional characteristics, aiming to provide better efficacy and reduce drug frequency for the treatment of IBD.
艾伯维与明济生物签署许可协议 共同开发下一代炎症性肠病疗法
AbbVie and Mingenix Biotechnology have signed a licensing agreement to jointly develop the next generation of inflammatory bowel disease therapy.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.